Weston Sutherland
Weston Sutherland has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Hugo M. Vargas
Translational Safety & Bioanalytical Sciences Amgen Research Thousand Oaks California USA
2 shared publications - Michael J. Engwall
Amgen Research
2 shared publications Aarif Y. Khakoo
Amgen Research, South San Francisco, California, USA
1 shared publication- Andrea Boden
Amgen Research, Thousand Oaks, California, USA
1 shared publication - BaoXi Gao
Amgen Research, Translational Safety & Bioanalytical Sciences, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
1 shared publication - Brandon Ason
Amgen Research, Department of Cardiometabolic Disorders, Amgen, South San Francisco, California, USA
1 shared publication
Latest Publications
- 22 October 2024
- Published by Springer Nature
- p. 969-984
Safety Pharmacology Evaluation of Biopharmaceuticals
- 22 October 2024
- Published by Springer Nature
- p. 969-984
Safety Pharmacology Evaluation of Biopharmaceuticals
- 2 December 2022
- Published by Springer Nature
- p. 1-16
Safety Pharmacology Evaluation of Biopharmaceuticals
- 2 December 2022
- Published by Springer Nature
- p. 1-16
Safety Pharmacology Evaluation of Biopharmaceuticals
- 23 April 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (8)
Cardiovascular response to small-molecule APJ activation
Heart failure (HF) remains a grievous illness with poor prognosis even with optimal care. The apelin receptor (APJ) counteracts the pressor effect of angiotensin II, attenuates ischemic injury, and has the potential to be a novel target to treat HF. Intravenous administration of apelin improves cardiac function acutely in patients with HF. However, its short half-life restricts its use to infusion therapy. To identify a longer acting APJ agonist, we conducted a medicinal chemistry campaign, leading to the discovery of potent small-molecule APJ agonists with comparable activity to apelin by mimicking the C-terminal portion of apelin-13. Acute infusion increased systolic function and reduced systemic vascular resistance in 2 rat models of impaired cardiac function. Similar results were obtained in an anesthetized but not a conscious canine HF model. Chronic oral dosing in a rat myocardial infarction model reduced myocardial collagen content and improved diastolic function to a similar extent as losartan, a RAS antagonist standard-of-care therapy, but lacked additivity with coadministration. Collectively, this work demonstrates the feasibility of developing clinical, viable, potent small-molecule agonists that mimic the endogenous APJ ligand with more favorable drug-like properties and highlights potential limitations for APJ agonism for this indication.
- 23 April 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (8)
Cardiovascular response to small-molecule APJ activation
Heart failure (HF) remains a grievous illness with poor prognosis even with optimal care. The apelin receptor (APJ) counteracts the pressor effect of angiotensin II, attenuates ischemic injury, and has the potential to be a novel target to treat HF. Intravenous administration of apelin improves cardiac function acutely in patients with HF. However, its short half-life restricts its use to infusion therapy. To identify a longer acting APJ agonist, we conducted a medicinal chemistry campaign, leading to the discovery of potent small-molecule APJ agonists with comparable activity to apelin by mimicking the C-terminal portion of apelin-13. Acute infusion increased systolic function and reduced systemic vascular resistance in 2 rat models of impaired cardiac function. Similar results were obtained in an anesthetized but not a conscious canine HF model. Chronic oral dosing in a rat myocardial infarction model reduced myocardial collagen content and improved diastolic function to a similar extent as losartan, a RAS antagonist standard-of-care therapy, but lacked additivity with coadministration. Collectively, this work demonstrates the feasibility of developing clinical, viable, potent small-molecule agonists that mimic the endogenous APJ ligand with more favorable drug-like properties and highlights potential limitations for APJ agonism for this indication.